Skip to main navigation

About
Portfolio
- - Portfolio
- Cardio Health
  - Bezalip SR
  - Fibricor
  - Viskazide
  - Visken
  - Yosprala
  - Zontivity
  - Toprol-XL
- Pain Management
  - Cambia
  - Durela
  - Fiorinal
  - Fiorinal C
  - MT 400
  - NeoVisc
  - Treximet
  - Uracyst
  - Vimovo
- Other Products
  - Balanse
  - Balanse Diaflor
  - Balanse Kids
  - Blexten
  - Collatamp G
  - Iberogast
  - Moviprep
  - Mutaflor
- - Normacol
  - Pegalax
  - Proferrin
  - Purfem
  - Resultz
  - Soriatane
Investors
Investor Relations2
News
Investor news main menu
Careers
- - Careers
- More Information
  - Working at Aralez
  - Recruiting Agencies
Contact Us

About
- History
  - Our Mission
- Leadership
  - Management
Portfolio
- Cardiovascular
  - Bezalip SR
  - Fibricor
  - Viskazide
  - Visken
  - YOSPRALA
  - Zontivity
- Pain
  - Cambia
  - Durela
  - Fiorinal
  - FiorinalC
  - NeoVisc
  - Treximet
  - Uracyst
  - Vimovo
  - MT400
- Other Specialties
  - Balanse
  - Balanse Diaflor
  - Balanse Kids
  - CollatampG
  - Iberogast
  - MoviPrep
  - Mutaflor
  - PegaLAX
  - Proferrin
  - Purfem
  - Resultz
Investors
Investor Relations2
News
Investor news main menu
Careers
- External Recruiting Agencies
Contact Us

Investors

Investor news main menu

Aralez Pharmaceuticals
- News Archive
- Historical Presentations
POZEN
Tribute

Tools

Print Page
RSS Feeds
Email Alerts
IR Contact Information

Error message

An illegal choice has been detected. Please contact the site administrator.

Tribute Pharmaceuticals News Archive

Keyword Search

Year:

There are currently no news releases to display.

Copyright West LLC. Minimum 15 minutes delayed.

About Aralez

The combination of POZEN Inc. and Tribute Pharmaceuticals represents an important strategic transformation, creating Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform.

News Releases

PRESS RELEASES

Summary Toggle Aralez Pharmaceuticals Completes Sale of Vimovo Royalties and Canadian Operations to Nuvo Pharmaceuticals
Summary Toggle Aralez Pharmaceuticals to Seek Court Approval of Previously Announced "Stalking Horse" Transactions for Substantially All Assets
Summary Toggle Aralez Pharmaceuticals Enters Into Definitive "Stalking Horse" Purchase Agreements For Substantially All Assets

Site Map

Home
About
Portfolio
Investors
News
Careers
Contact Us

Contact Info

Email: info@aralez.com
Sign up for news alerts
Legal Notice
Privacy Policy

© 2019 Aralez Pharmaceuticals Inc.

Hosted and managed by Body1